Table 1.
Drug formulation | IC50 (μM)
|
|||
---|---|---|---|---|
MCF7
|
MCF7/ADR
|
|||
48 hours | 96 hours | 48 hours | 96 hours | |
Free Dox | 2.43±0.22 | 0.61±0.17 | 49.39±2.58 | 29.96±1.46 |
Free NLS-Dox | 6.23±0.37 | 1.21±0.25 | 16.49±1.73 | 4.85±0.83 |
HMNs (NLS-Dox + scramble inhibitor) | 8.69±1.03 | 1.8±0.36 | 14.93±1.52 | 4.26±0.39 |
HMNs (NLS-Dox + anti-miR21) | 6.69±0.45 | 0.35±0.08 | 6.06±0.71 | 1.02±0.27 |
Abbreviations: IC50, half-maximal inhibitory concentration; Dox, doxorubicin; NLS, nuclear localization signal; HMNs, high-density lipoprotein-mimicking nanoparticles; miR21, microRNA21.